University of Canberra Researchers to Use Medical Marijuana to Treat Melanoma Patients; Trials to Begin Soon
University of Canberra researchers will be collaborating with a pharmaceutical company to test the effectiveness of medical marijuana in treating melanoma. Israel-based Cann Pharmaceutical will be providing specific medical-grade strains of cannabis with the university announcing a $1 million deal with the company. The cannabis strains will be administered to patients with current standard of care for melanoma sufferers. Clinical trials are set to begin in the ACT next year.
The two-year research project would be led by cellular and molecular biologist professor Sudha Rao, who will analyse how cannabis may be used together with radiation and other therapies to treat skin cancer. Cann Pharmaceutical Australia’s managing director Andrew McCrea believes that results of the first trials may be obtained as soon as next year. Rao thinks the research may benefit nearly 55,000 Australians who live with skin cancer.
“Australians have the highest rate of melanoma in the world, with...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin